146 related articles for article (PubMed ID: 21177764)
21. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
22. Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen.
Glinkina K; Groenewoud A; Teunisse AFAS; Snaar-Jagalska BE; Jochemsen AG
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804957
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Hemming ML; Bhola P; Loycano MA; Anderson JA; Taddei ML; Doyle LA; Lavrova E; Andersen JL; Klega KS; Benson MR; Crompton BD; Raut CP; George S; Letai A; Demetri GD; Sicinska E
Clin Cancer Res; 2022 Jun; 28(11):2397-2408. PubMed ID: 35325095
[TBL] [Abstract][Full Text] [Related]
24. Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer.
Truong DD; Lamhamedi-Cherradi SE; Ludwig JA
J Bone Oncol; 2022 Apr; 33():100419. PubMed ID: 35251924
[TBL] [Abstract][Full Text] [Related]
25. Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond.
de Bernardi A; Dufresne A; Mishellany F; Blay JY; Ray-Coquard I; Brahmi M
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205812
[TBL] [Abstract][Full Text] [Related]
26. Metabolic Pathways and Targets in Chondrosarcoma.
Micaily I; Roche M; Ibrahim MY; Martinez-Outschoorn U; Mallick AB
Front Oncol; 2021; 11():772263. PubMed ID: 34938658
[TBL] [Abstract][Full Text] [Related]
27. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.
Hemming ML; Fan C; Raut CP; Demetri GD; Armstrong SA; Sicinska E; George S
Mol Cancer Res; 2020 Sep; 18(9):1302-1314. PubMed ID: 32518213
[TBL] [Abstract][Full Text] [Related]
29. Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients.
Arena C; Troiano G; Zhurakivska K; Nocini R; Lo Muzio L
Onco Targets Ther; 2019; 12():9669-9683. PubMed ID: 31814732
[TBL] [Abstract][Full Text] [Related]
30. IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors.
Andersson MK; Åman P; Stenman G
Cells; 2019 Aug; 8(8):. PubMed ID: 31426421
[TBL] [Abstract][Full Text] [Related]
31. Management consideration for patient with a large solitary fibrous tumor occupying the infratemporal fossa: A case report.
Saito M; Senjo H; Kanaya M; Izumiyama K; Mori A; Tanaka M; Morioka M; Miyashita K; Ishida Y
Mol Clin Oncol; 2018 Apr; 8(4):544-548. PubMed ID: 29556387
[TBL] [Abstract][Full Text] [Related]
32. Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
Faes S; Santoro T; Demartines N; Dormond O
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29104248
[TBL] [Abstract][Full Text] [Related]
33. Managing sarcoma: where have we come from and where are we going?
Bleloch JS; Ballim RD; Kimani S; Parkes J; Panieri E; Willmer T; Prince S
Ther Adv Med Oncol; 2017 Oct; 9(10):637-659. PubMed ID: 28974986
[TBL] [Abstract][Full Text] [Related]
34. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Rugo HS; Trédan O; Ro J; Morales SM; Campone M; Musolino A; Afonso N; Ferreira M; Park KH; Cortes J; Tan AR; Blum JL; Eaton L; Gause CK; Wang Z; Im E; Mauro DJ; Jones MB; Denker A; Baselga J
Breast Cancer Res Treat; 2017 Oct; 165(3):601-609. PubMed ID: 28681171
[TBL] [Abstract][Full Text] [Related]
36. Anti-angiogenesis target therapy for advanced osteosarcoma (Review).
Xie L; Ji T; Guo W
Oncol Rep; 2017 Aug; 38(2):625-636. PubMed ID: 28656259
[TBL] [Abstract][Full Text] [Related]
37. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.
Frezza AM; Stacchiotti S; Gronchi A
BMC Med; 2017 Jun; 15(1):109. PubMed ID: 28571564
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy for soft tissue sarcomas in adolescents and young adults.
Steppan DA; Pratilas CA; Loeb DM
Adolesc Health Med Ther; 2017; 8():41-55. PubMed ID: 28408855
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Baselga J; Morales SM; Awada A; Blum JL; Tan AR; Ewertz M; Cortes J; Moy B; Ruddy KJ; Haddad T; Ciruelos EM; Vuylsteke P; Ebbinghaus S; Im E; Eaton L; Pathiraja K; Gause C; Mauro D; Jones MB; Rugo HS
Breast Cancer Res Treat; 2017 Jun; 163(3):535-544. PubMed ID: 28324268
[TBL] [Abstract][Full Text] [Related]
40. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Drug Des Devel Ther; 2016; 10():2575-97. PubMed ID: 27574398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
